RxDoctor Payments Data

Rachel Venable

Adult Health · Richmond, VANPI 1689029597

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,594 of the $4,810 with a category attached, or 74.7%. 10 manufacturers reported payments, led by Cvrx, Inc. at 54.5% of the total. 2025 is the largest year on record at $3,216, more than ten times the $95 reported in 2021.

$4,810in general payments, 2019–2025

Across 38 payments — averaging $126.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$3K
  • Abbott$1K
  • AstraZeneca$217
  • Boston Scientific$138
  • Kiniksa Pharmaceuticals International, PLC$133
  • E.r. Squibb & Sons, L.L.C.$124
  • plus $379 from 4 others

What the payments were for

  • Travel & lodging$1,21625%
  • Food & beverage$3,59475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,810 in reported general payments places this provider in the 85th percentile of 368 adult health providers in Virginia.

See all adult health providers in Virginia

Medicare billing

Part B allowed, 2024
$22,151
Medicare patients
134
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan350$382,225
JardianceEmpagliflozin190$224,293
EliquisApixaban139$142,728
FarxigaDapagliflozin Propanediol72$71,687
XareltoRivaroxaban29$18,864
Repatha SureclickEvolocumab22$11,746
Torsemide204$6,824
Bumetanide49$3,428
Metoprolol Succinate244$2,291
Amiodarone Hcl61$2,038
Spironolactone347$1,953
Isosorbide Dinitrate28$1,498
Carvedilol246$1,379
Furosemide273$1,281
Hydralazine Hcl82$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$217$71,68772 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 adult health providers in Virginia.

Other adult health in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →